Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Positron emission tomography with computed tomography (PET/CT) and minimal residual disease (MRD) for efficacy assessment in transplant-ineligible newly diagnosed myeloma (Ti NDMM) patients (pts): IMROZ analysis.
Elena Zamagni, Thierry Façon, Meletios A Dimopoulos, Xavier P. Leleu, Meral Beksaç, Luděk Pour, Roman Hájek, Zhuogang Liu, Jiří Minařík, Philippe Moreau, Joanna Romejko‐Jarosińska, Ivan Spicka, Tom Martin, Lugui Qiu, Christos Sachpekidis, Ercem Kodas, Helgi van de Velde, Liang Zhao, Robert Orlowski, Hartmut Goldschmidt (2025). Positron emission tomography with computed tomography (PET/CT) and minimal residual disease (MRD) for efficacy assessment in transplant-ineligible newly diagnosed myeloma (Ti NDMM) patients (pts): IMROZ analysis.. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.7551.
Article42 days agoCirculating tumor cells (CTCs) improve risk stratification according to the second revision of the international staging system (R2-ISS) and the ims-IMWG consensus genomic staging (CGS) in newly diagnosed multiple myeloma (NDMM): An analysis from the european CTC consortium.
Mattia D’Agostino, Esperanza Martín‐Sánchez, David Žihala, Ioannis V. Kostopoulos, Juan-José Garcés, Noemí Puig, Giuseppe Bertuglia, Tereza Ševčíková, Tom Cupedo, Mark van Duin, Jonathan J. Keats, Elena Zamagni, Philippe Moreau, Sonja Zweegman, Jill Corre, Mario Boccadoro, Meletios A Dimopoulos, Roman Hájek, Bruno Paiva, Pieter Sonneveld, Annemiek Broijl, Evangelos Terpos, Tomáš Jelı́nek, Jesús F. San Miguel, Francesca Gay, Luca Bertamini (2025). Circulating tumor cells (CTCs) improve risk stratification according to the second revision of the international staging system (R2-ISS) and the ims-IMWG consensus genomic staging (CGS) in newly diagnosed multiple myeloma (NDMM): An analysis from the european CTC consortium.. , 146(Supplement 1), DOI: https://doi.org/10.1182/blood-2025-364.
Article42 days agoSequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network
Niels W.C.J. van de Donk, Philippe Moreau, Jesús F. San Miguel, María‐Victoria Mateos, Meletios A Dimopoulos, Sonja Zweegman, Francesca Gay, Monika Engelhardt, Roberto Mina, Elena Zamagni, Michel Delforge, Meral Beksaç, Andrew Spencer, Fredrik Schjesvold, Christoph Driessen, Martin Kaiser, Aurore Perrot, Ralph Wäsch, Charlotte L.B.M. Korst, Annemiek Broijl, Cyrille Touzeau, Salomon Manier, Roman Hájek, Jelena Bila, Güldane Cengiz Seval, Michael O’Dwyer, Heinz Ludwig, Carlos Fernández de Larrea, Rakesh Popat, Pellegrino Musto, Paula Rodríguez‐Otero, Kwee Yong, K. Martin Kortüm, Leo Rasche, Evangelos Terpos, Marc S. Raab, Mario Boccadoro, Pieter Sonneveld, Hermann Einsele (2025). Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network. , 9(11), DOI: https://doi.org/10.1002/hem3.70260.
Article42 days agoEHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma
Meletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, Philippe Moreau, María‐Victoria Mateos, Sonja Zweegman, Gordon Cook, Monika Engelhardt, Michel Delforge, Roman Hájek, Fredrik Schjesvold, Francesca Gay, Morten Salomo, Katja Weisel, Martin Kaiser, Niels W.C.J. van de Donk, Elena Zamagni, Paula Rodríguez‐Otero, Aurore Perrot, Christoph Driessen, Jelena Bila, Edward Laane, Dominik Dytfeld, Cyrille Touzeau, Meral Beksac, Marc S. Raab, Michèle Cavo, Mohamad Mohty, Andrew Spencer, Heinz Ludwig, Hermann Einsele, Jesús F. San Miguel, Pieter Sonneveld (2025). EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. , 22(9), DOI: https://doi.org/10.1038/s41571-025-01041-x.
Article42 days agoIsatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) in newly diagnosed multiple myeloma (NDMM): Outcomes in patients with 1q21+ status in the phase 3 IMROZ study.
Meletios A Dimopoulos, Xavier P. Leleu, Meral Beksaç, Luděk Pour, Roman Hájek, Zhuogang Liu, Jiří Minařík, Philippe Moreau, Joanna Romejko‐Jarosińska, Ivan Spicka, Vladimir Vorobyev, Elena Zamagni, Hartmut Goldschmidt, Thomas G. Martin, Robert Orlowski, Zandra Klippel, Umer Khan, Sandrine Macé, Helgi van de Velde, Thierry Façon (2025). Isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) in newly diagnosed multiple myeloma (NDMM): Outcomes in patients with 1q21+ status in the phase 3 IMROZ study.. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.7517.
Article42 days ago